Table 1 Detailed information on 45 cited articles

1

Aizer

2009

Radiother Oncol

93

185–191

2

Alicikus

2011

Cancer

117

1429–1437

3

Cahlon

2008

IJROBP

71

330–337

4

Eade

2007

IJROBP

68

682–689

5

Kuban

2008

IJROBP

70

67–74

6

Lukka

2005

J Clin Oncol

23

6132–6138

7

Valdagni

2005

Radiother Oncol

75

74–82

8

Zelefsky

2008

IJROBP

71

1028–1033

9

Miralbell

2012

IJROBP

82

e17–24

10

Arcangeli

2012

IJROBP

84

1172–1178

11

Catton

2017

J Clin Oncol

35

1884–1890

12

Dearnaley

2016

The Lancet Oncology

17

1047–1060

13

Incrocci

2016

The Lancet Oncology

17

1061–1069

14

Kim

2014

Radiat Oncol J

32

187–197

15

Kupelian

2005

IJROBP

63

1463–1468

16

Leborgne

2009

IJROBP

74

1441–1446

17

Leborgne

2012

IJROBP

82

1200–1207

18

Pollack

2013

J Clin Oncol

31

3860–3868

19

Yeoh

2006

IJROBP

66

1072–1083

20

Cheung

2016

IJROBP

96

S33

21

Di Muzio

2016

Clin Oncol (R Coll Radiol)

28

490–500

22

Faria

2011

Radiother Oncol

101

486–489

23

Fonteyne

2012

IJROBP

84

e483–490

24

Hashimoto

2017

Int J Clin Oncol

NA

NA

25

Kuban

2010

IJROBP

78

S58–59

26

Kupelian

2007

IJROBP

68

1424–1430

27

Lieng

2017

Radiother Oncol

122

93–98

28

Livsey

2003

IJROBP

57

1254–1259

29

Mai

2010

IJROBP

78

S59

30

Patel

2013

IJROBP

86

534–539

31

Pervez

2017

Am J Clin Oncol

40

200–206

32

Shimizu

2017

Anticancer Res

37

5829–5835

33

Thomson

2012

Prostate Cancer

NA

NA

34

Viani

2016

Rep Pract Oncol Radiother

21

162–167

35

Bolzicco

2013

BMC Urol

13

NA

36

Fuller

2014

Front Oncol

4

NA

37

Kang

2011

Tumori

97

43–48

38

Katz

2013

Radiat Oncol

8

NA

39

King

2013

Radiother Oncol

109

217–221

40

Lee

2014

Medicine (Baltimore)

93

e290

41

Loblaw

2013

Radiother Oncol

107

153–158

42

Mantz

2014

Front Oncol

4

NA

43

Meier

2016

IJROBP

96

S33–34

44

Tsang

2021

Radiother Oncol

158

184–190

45

Chin,S

2020

IJROBP

107

288–296